To this end, CMS5a-NY-ESO-1-bearing mice were treated with anti-CD25 mAb or anti-CTLA-4 mAb, both of which reportedly induce tumor regression via depleting Tregs,32 in combination with anti-PD-1 mAb. The gene discussed is CTLA4; the disease is neoplasm.